12 Jul 2013
Myriad Genetics, a biotech company, owns patents on the BRCA1 and BRCA2 genes, mutations of which help to increase the risk of certain breast and ovarian cancers. The Association for Molecular Pathology filed a suit against Myriad in 2009, claiming that the genes, which are naturally occurring segments of DNA, are not eligible for a...
21 Jun 2013
The past twenty-five years have seen amazing advancement in scientific understanding of the human body. From cloning to stem cells, major scientific breakthroughs have turned the body itself into a kind of technology to be manipulated and played with. But the crowning achievement of this new research into the human body is arguably the Human...
20 Jun 2013
On Thursday, June 13, 2013, the United States Supreme Court posted, in a 9-0 count, that isolated human genes do not qualify as patentable subject matter. Myriad Genetics, a biotech company, owns patents for the BRCA1 and BRCA2 genes, mutations of which help to increase the risk for particular breast and ovarian cancers. The question...